Quanterix

Company QTRX

Last mentioned: Mar 4, 2026

Timeline

  1. Earnings Call

    Management confirms CMS reimbursement rate of $897 and 2025 assay expansion.

  2. FDA Submission

    510(k) premarket notification submitted for Lucent AD Complete.

  3. Q4 2025 Close

    Quanterix reports $43.9M in revenue with 25% YoY growth.

Stories mentioning Quanterix 1

Medical Devices Bullish

Quanterix Secures CMS Reimbursement for Alzheimer’s Test Amid Q4 Growth

Quanterix reported a 25% year-over-year revenue increase to $43.9 million in Q4 2025, driven by a surge in diagnostics partner revenue and critical regulatory milestones. The company achieved a commercial breakthrough with a $897 CMS reimbursement rate for its Lucent AD Complete test, positioning it for large-scale clinical adoption.

6 sources